The estimated Net Worth of Bernhard E. Spiess is at least $7.26 Milion dollars as of 10 December 2021. Mr. Spiess owns over 1,500 units of Castle Biosciences stock worth over $467,374 and over the last 5 years he sold CSTL stock worth over $6,796,778. In addition, he makes $0 as Chief Business Officer at Castle Biosciences.
Bernhard has made over 9 trades of the Castle Biosciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of CSTL stock worth $46,545 on 10 December 2021.
The largest trade he's ever made was selling 40,000 units of Castle Biosciences stock on 1 December 2020 worth over $1,998,800. On average, Bernhard trades about 17,113 units every 48 days since 2019. As of 10 December 2021 he still owns at least 15,062 units of Castle Biosciences stock.
You can see the complete history of Mr. Spiess stock trades at the bottom of the page.
Bernhard E. Spiess serves as Chief Business Officer of the Company. Mr. Bernhard E. Spiess was our Chief Operating Officer from May 2016 to September 2019. From April 1997 to April 2016, Mr. Spiess held various positions with Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, including as Vice President, Strategic Marketing, Blood Virus & Infectious Diseases from February 2015 to April 2016, and as Vice President, Marketing, Molecular Diagnostics from April 2008 to February 2015. Throughout his career, Mr. Spiess has held positions of increasing responsibility in laboratory testing and management, scientific support, sales, strategic and tactical marketing, and product and business management. Mr. Spiess holds a B.App.Sc. degree in Medical Technology from the Royal Melbourne Institute of Technology.
Bernhard Spiess is 60, he's been the Chief Business Officer of Castle Biosciences since 2019. There are 2 older and 10 younger executives at Castle Biosciences. The oldest executive at Castle Biosciences, Inc. is David Kabakoff, 72, who is the Independent Director.
Bernhard's mailing address filed with the SEC is C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, STE. 401, FRIENDSWOOD, TX, 77546.
Over the last 5 years, insiders at Castle Biosciences have traded over $378,509,770 worth of Castle Biosciences stock and bought 782,652 units worth $12,524,690 . The most active insiders traders include Daniel Bradbury, Derek J Maetzold a Joseph C. Iii Cook. On average, Castle Biosciences executives and independent directors trade stock every 6 days with the average trade being worth of $632,640. The most recent stock trade was executed by Derek J Maetzold on 9 September 2024, trading 2,586 units of CSTL stock currently worth $76,184.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Castle Biosciences executives and other stock owners filed with the SEC include: